Clinical trials: Adjuvant Treatment
Prostate Cancer
Neoadjuvant And Adjuvant Abiraterone Acetate + Apalutamide Prostate Cancer Undergoing Prostatectomy
This multicenter randomized phase II trial investigates the impact of intense androgen deprivation on radical prostatectomy (RP) pathologic response and radiographic and tissue biomarkers in localized prostate cancer…
- Trial name
- NCT02903368
- Testing
- Apalutamide, Leuprolide, Prednisone
- Where
- 4 sites in United States
- Volunteers
- 118 people
- Sponsor
- Dana-Farber Cancer Institute
Esophageal Squamous Cell Carcinomas
Camrelizumab Combined With Radiotherapy for Adjuvant Treatment of Esophageal Squamous Cell Carcinoma After Surgery
This is an investigator-initiated, single-arm, single-center, exploratory clinical study.The study population consisted of patients with R0 resection of esophageal squamous cell carcinoma who had not received radiation…
- Trial name
- NCT04741490
- Testing
- Camrelizumab, radiotherapy
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Fuzhou General Hospital
Intermittent Claudication, Peripheral Vascular Disease
Adjuvant Benefit of NMES to Supervised Exercise in Patients With IC
This study will assess the adjuvant benefit of a neuromuscular electrical stimulation device to standard treatment of supervised exercise in patients suffering from symptoms and effects of lower limb Intermittent Claudication.
- Conditions
- Intermittent Claudication, Peripheral Vascular Disease, Lower Limb Arterial Disease
- Trial name
- AdjIC (NCT02429310)
- Testing
- Revitive IX
- Where
- United Kingdom
- Volunteers
- 42 people
- Sponsor
- Imperial College London
Breast Cancer Early Stage Breast Cancer (Stage 1-3)
FLASH-Breast: Evaluating the Efficacy of Fezolinetant in Reducing Vasomotor Symptoms in Women With Breast Cancer on Endocrine Therapy
This is a phase II, randomized, double-blinded, placebo-controlled trial designed to evaluate the efficacy of fezolinetant (45 mg a day) vs.
- Trial name
- NCT06917313
- Testing
- Fezolinetant
- Where
- 2 sites in United States
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Yale University
Esophageal Cancer
Volume Outcome Relationships and Effects
This is a retrospective analysis to assess if high-volume hospital facilities experience greater or lesser rates of incidence in patients with esophageal cancer than low-volume facilities.
- Trial name
- NCT06343597
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Methodist Health System
Hepatocellular Carcinoma
A Trial of Adjuvant Therapy After Hepatocarcinoma Resection Based on Folate Receptor-positive Circulating Tumor Cells
The aim of this study is to analyze the therapeutic effect of postoperative adjuvant chemotherapy with FOLFOX4 after hepatocarcinoma resection based on folate receptor-positive circulating tumor cells.
- Trial name
- NCT04521491
- Testing
- FOLFOX4(infusional fluorouracil [FU], leucovorin [LV], and oxaliplatin [OXA]).
- Where
- China
- Volunteers
- 184 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Naive Unresectable Glioblastoma
Evaluation of the Irinotecan/Bevacizumab Association for Naive Unresectable Glioblastoma
Treatment of glioblastoma (GBM) is based on surgery when possible, and chemoradiation with temozolomide, which became a standard since the EORTC study (Stupp, 2005).
- Trial name
- TemAvIr (NCT01022918)
- Testing
- Avastin + Campto / radiotherapy + Temodal + Avastin (4 cures), Temodal/radiotherapy
- Where
- France
- Volunteers
- 134 people
- Sponsor
- Centre Georges Francois Leclerc
Hormone Receptor-positive Advanced Breast Cancer
Combination of Chidamide and Fulvestrant for HR+/HER2- Breast Cancer That Has Failed Previous CDK4/6 i Adjuvant Therapy
This trial is a single-arm study. The purpose of the trial is to evaluate the efficacy and safety of chidamide and fulvestrant in HR+/HER2- breast cancer that has failed prior adjuvant endocrine therapy with CDK4/6 inhibitors.
- Trial name
- NCT05806047
- Testing
- chidamide combined with fulvestrant
- Volunteers
- 23 people
- Sponsor
- Fudan University
Squamous Cell Carcinoma of Head and Neck
Navigation for Timely Adjuvant Therapy for Patients With Locally Advanced HNSCC
Head and neck cancer squamous cell carcinoma (HNSCC) is a disease with poor survival, especially for African Americans, despite intense treatment including surgery, radiation, and chemotherapy.
- Trial name
- NCT04098458
- Testing
- NDURE
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Medical University of South Carolina
Recurrent Colon Cancer, Extensive Stage Small Cell Lung Cancer
Vaccine Therapy in Treating Patients With Colon, Pancreatic, or Lung Cancer
RATIONALE: Vaccines made from mutated ras peptides may make the body build an immune response to and kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of a vaccine containing mutated ras peptides and an immune…
- Conditions
- Recurrent Colon Cancer, Extensive Stage Small Cell Lung Cancer, Stage III Pancreatic Cancer, Stage III Rectal Cancer
- Trial name
- NCT00019006
- Testing
- Detox-B adjuvant, ras peptide cancer vaccine
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
Oral Vinorelbine or Capecitabine Combined With Trastuzumab as Adjuvant Treatment for Patients With Lymph Node Negative, HER-2 Positive and Small Tumor Size Breast Cancer (ORCHID)
This is a prospective, open-lable Phase II clinical trial (ORCHID study) evaluating the effectiveness and safety of oral vinorelbine or capecitabine combined with trastuzumab as adjuvant treatment for patients with lymph node…
- Trial name
- ORCHID (NCT04296162)
- Testing
- Vinorelbine, Capecitabine, Trastuzumab
- Where
- China
- Volunteers
- 182 people
- Sponsor
- Fudan University
Breast Cancer
A Clinical Trial of Breast Cancer Neo-adjuvant Therapy Based on Molecular Pathway in FUSCC
This is a Phase Ib/II, prospective , open-label, single center, Bayesian adaptive design, umbrella study evaluating the efficacy and safety of neo-adjuvant therapy in patients with breast cancer.
- Trial name
- NCT04215003
- Testing
- A, B, CL4
- Where
- 2 sites in China
- Volunteers
- 20 people
- Sponsor
- Fudan University
Estrogen Receptor-positive Breast Cancer, HER2-positive Breast Cancer
Doxorubicin Hydrochloride, Cyclophosphamide, and Filgrastim Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation With or Without Trastuzumab in Treating Patients With Breast Cancer Previously Treated With Surgery
RATIONALE: Drugs used in chemotherapy, such as doxorubicin hydrochloride, cyclophosphamide, and paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing…
- Conditions
- Estrogen Receptor-positive Breast Cancer, HER2-positive Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer
- Trial name
- NCT00407888
- Testing
- doxorubicin hydrochloride, cyclophosphamide, filgrastim
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Washington
Hepatocellular Carcinoma
Multicenter RCT of ADV-TK Gene Therapy Improving the Outcome of Liver Transplantation for Advanced HCC
Compare the effect of liver transplantation (LT) plus ADV-TK gene therapy versus LT only in advanced primary hepatocellular carcinoma.
- Trial name
- NCT03313596
- Testing
- ADV-Tk, LT
- Where
- 11 sites in China
- Volunteers
- 180 people
- Sponsor
- Huazhong University of Science and Technology
Rectal Mucinous Adenocarcinoma, Rectal Signet Ring Cell Adenocarcinoma
Comparison of Adjuvant Chemotherapy Regimens in Treating Stage II/III Rectal Cancer
This randomized phase III trial is comparing the effectiveness of three adjuvant combination chemotherapy regimens in treating patients who are receiving radiation therapy and fluorouracil either before or after surgery for stage…
- Conditions
- Rectal Mucinous Adenocarcinoma, Rectal Signet Ring Cell Adenocarcinoma, Recurrent Rectal Carcinoma, Stage IIA Rectal Cancer AJCC v7
- Trial name
- NCT00068692
- Testing
- Radiotherapy, Fluorouracil, Leucovorin Calcium
- Where
- United States
- Volunteers
- 225 people
- Sponsor
- National Cancer Institute (NCI)
COVID-19
Hydroxychloroquine and Nitazoxanide Combination Therapy for COVID-19
In December 2019, a new infectious respiratory disease emerged in Wuhan, Hubei province, China. An initial cluster of infections was linked to Huanan seafood market, potentially due to animal contact.
- Trial name
- NCT04361318
- Testing
- Hydroxychloroquine plus Nitazoxanide, Standard care
- Volunteers
- 100 people
- Sponsor
- Tanta University
Digestive System Neoplasms
Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Subjects With Resected Digestive System Neoplasms
The purpose of this study is to assess the safety, feasibility, and efficacy of personalized mRNA vaccine iNeo-Vac-R01 with standard adjuvant therapy in subjects with surgically resected digestive system neoplasms.
- Trial name
- NCT06026774
- Testing
- iNeo-Vac-R01 in combination with standard adjuvant therapy
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Sir Run Run Shaw Hospital
Upper Urinary Tract Urothelial Carcinoma
A Clinical Study of the Efficacy and Safety of Disitamab Vedotin in Combination With Radiotherapy for the Adjuvant Treatment of HER2 Overexpressing UTUC Patients With High Risk Factors for Recurrence After Radical Surgery
In this study, 60 patients with HER2 overexpression UTUC with high-risk recurrence factors after radical surgery were proposed to be enrolled, and were assigned to Cohort I (receiving adjuvant therapy group) and Cohort II…
- Trial name
- NCT06210490
- Testing
- Disitamab Vedotin, Radiotherapy, Standard of Care
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking University First Hospital
Renal Neoplasms, Targeted Molecular Therapy
A CpG-methylation-based Assay for Stratifying Stage III Clear Cell Renal Cell Carcinoma of Receiving Adjuvant Treatment
Whether patients with stage III clear cell renal cell carcinoma(ccRCC) should receive adjuvant targeted therapy or not is still on debate.
- Trial name
- NCT02688491
- Testing
- sunitinib
- Volunteers
- 300 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Hypoxic Ischemic Encephalopathy
Topiramate in Neonates Receiving Whole Body Cooling for Hypoxic Ischemic Encephalopathy
The goal is to see whether topiramate (an anti-epileptic agent) improves the outcome of babies with neonatal hypoxic encephalopathy who are receiving whole body cooling.
- Trial name
- NCT01765218
- Testing
- Topiramate
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Kristin R Hoffman
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.